Psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger. e) History of life-threatening toxicity related to prior immune therapy (eg, anti-CTLA-4 or anti-PD-1/PD-L1 treatment or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways) except those that are unlikely to re-occur with standard countermeasure s (eg, hormone replacement after adrenal crisis). f) Interstitial lung disease that is symptom atic or that may interfere with the detection or management of suspected drug-related pulmonary toxicity. g) Conditions requiring systemic treatment w ith either corticosteroids > 10 mg daily prednisone equivalents or other immunosuppressive med ications within 14 days of study treatment administr ation, except for adrenal replacement steroid doses ≤10 mg daily prednisone equivalent in the absence of active autoimmune disease. ii) Treatment with a short course of steroids (< 5 days) up to 7 days prior to initiating study treatmen t is permitted. h) Uncontrolled or significant cardiovasc ular disease incl uding, but not limited to, any of the following: i) Myocardial infarction or stroke/transient ischemic attack within the past 6 months.ii) Uncontrolled angina within the past 3 months. iii) Any history of clinically significant arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or torsades de pointes). iv) History of other clinically significant heart disease (eg, myocarditis, cardiomyopathy, congestive heart failure with New York Heart Association functional classification III to IV [ Appendix 9 ], pericarditis, or significant pericardial effusion). v) Cardiovascular disease-related requirement for daily supplemental oxygen therapy. vi) QT interval corrected for heart rate using Fridericia’s formula (QTcF) prolongation > 480 msec, except for right bundle branch block. i) History of chronic hepatitis as evidenced by the following: i) Any positive test result for hepatitis B vi rus or hepatitis C virus indicating presence of virus, eg, hepatitis B surface antigen (Australia antigen) positive, or hepatitis C antibody positive (except if hepatitis C ribonucleic acid [RNA] negative). j) Evidence of active infection that requires systemic antibacterial, antiviral, or antifungal therapy ≤7 days prior to the first dose of study treatment (except for viral infections that are presumed to be associated with the underlying tumor type required for study entry). Revised Protocol No.: 04 Date: 31-May-2019 79 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS k) Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome. Note: Testing for HIV-1 and HIV-2 must be performed at sites where mandated by local requirements.